RxDoctor Payments Data

Megan Vargas, PA

Physician Assistant · Boerne, TXNPI 1396145124

Payments from drug & device makers

$15,751in general payments, 2019–2025

Across 968 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bristol Myers Squibb$1K
  • Biogen$975
  • Pfizer$849
  • Novartis$733
  • Teva Pharmaceuticals USA, Inc.$676
  • plus $9K from 49 others

What the payments were for

  • Food & beverage$15,66699%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,751 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$3,474
Medicare patients
35
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate57$91,206
UbrelvyUbrogepant30$33,846
Trokendi XrTopiramate11$17,910
Aimovig AutoinjectorErenumab-Aooe17$13,386
Ajovy SyringeFremanezumab-Vfrm12$8,150
VimpatLacosamide13$7,813
Topiramate ErTopiramate17$4,796
Eletriptan HbrEletriptan Hydrobromide14$1,848
Memantine Hcl82$1,721
Levetiracetam68$1,467
Primidone24$1,448
Lacosamide12$1,176
Pregabalin46$1,086
Modafinil20$830
Carbidopa-LevodopaCarbidopa/Levodopa18$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$849$91,20657 claims
AbbVieUbrelvy$2,367$33,84630 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$79$17,91011 claims
UCB, Inc.Vimpat$666$7,81313 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$75$71916 claims
Upsher-smith Laboratories LLCTopiramate$45$39458 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Boerne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →